Login
Search
Search
0 Dates
2026
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
CPC 2026
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Prevalence of eligibility for dual GIP/GLP-1 receptor agonists among non-diabetic and overweight adults: a Portuguese community-based study
Session:
Sessão de Posters 14 - Tratar o risco: sucessos e falhas na gestão lipídica
Speaker:
Helena Santos Moreira
Congress:
CPC 2026
Topic:
J. Preventive Cardiology
Theme:
28. Risk Factors and Prevention
Subtheme:
28.6 Obesity
Session Type:
Posters Eletrónicos
FP Number:
---
Authors:
Helena Santos Moreira; Benedita Viana; Giulia Rinaldi; Pedro Mangas Palma; Bernardo Cruz; Emanuel Oliveira; Francisca Saraiva; Silvia O Diaz; Mariana Vasconcelos; Marta Tavares Silva; Rui André Rodrigues; Adelino Leite Moreira
Abstract
<p style="text-align:justify"><strong>Background:</strong> Obesity stands as a potentially modifiable cardiovascular (CV) risk factor, with current guidelines including targeted therapy as part of standard of care. Recent evidence shows benefits of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists (RA) dual therapy in overweight and non-diabetic individuals, with significant weight loss and improved CV markers. In Portugal, reimbursement of dual RA therapy is not adressed, leaving many undertreated.<br /> <strong>Purpose:</strong> To assess and characterize the prevalence of non-diabetic and overweight adults potentially eligible for dual GIP/GLP-1 RA therapy in a community-based setting.<br /> <strong>Methods:</strong> A cross-sectional CV screening programme was conducted in three localities in Portugal. Screening included a standardized clinical assessment and onsite blood sampling. Eligibility for dual RA therapy with tirzepatide followed SURMOUNT-1 Trial criteria.<br /> <strong>Results:</strong> A total of 161 non-diabetic pts were included (out of 198 screened pts), mostly female (n=110, 68%), median age of 65 years (IQR 56,73) and median body mass index (BMI) of 27 Kg/m2 (IQR 24,29). Nearly half (n=68, 49%) were classified as high risk according to the 10-year risk estimate of CV disease in Europe.<br /> Based on the eligibility criteria (figure 1), more than one-third (n=62, 39%) were deemed eligible for tirzepatide, mainly due to BMI ≥ 30 Kg/m2 (n=32, 52%), followed by BMI ≥ 27 Kg/m2 with arterial hypertension and/or dyslipidemia (n=28, 46%).<br /> Eligible pts had higher waist circumference (103 cm vs 89 cm, p<0.001), as well as higher glycated hemoglobin (5.70% vs 5.50%, p=0.004) and triglycerides levels (146 mg/dL vs 120 mg/dL, p=0.003). Possibly due to more frequent statin treatment (n=44, 71% vs n=35, 35% p<0.001), eligible pts had lower low-density lipoprotein cholesterol (81 mg/dL vs 101 mg/dL, p=0.026). Other blood parameters, including lipoprotein(a) (21 mg/dL, p=0.7), serum creatinine (0.77 mg/dL, p=0.2), high-sensitivity c-reactive protein (1.10 mg/dL p=0.095) and N-terminal pro–B-type natriuretic peptide (79 pg/mL, p>0.9) levels were similar across groups.<br /> Stable mental health disorders were more prevalent in eligible pts (n=21, 34% vs n=17, 17%, p=0.015) with no major differences in other chronic conditions. Although Atlantic dietary pattern (p=0.060), alcohol intake (p=0.072) and smoking history (p=0.4) were similar, eligible pts reported significantly less rates of aerobic physical activity per week (n=48, 77% vs n=92, 92%, p=0.004). Despite the high eligibility rate, none of the pts was under dual RA therapy.<br /> <strong>Conclusions:</strong> A substantial proportion of our community-based sample met the eligibility criteria for tirzepatide, yet none of the pts were currently under it. These findings support the need for updated health policies to possibly ensure wider access for dual RA therapy.</p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site